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Bladder cancer occurs in the epithelial lining of the urinary bladder and is amongst the most common types of cancer in humans,
killing thousands of people a year. This paper is based on the hypothesis that the use of clinical and histopathological data together
with information about the concentration of various molecular markers in patients is useful for the prediction of outcomes and the
design of treatments ofnonmuscle invasive bladder carcinoma (NMIBC).Apopulation of 45 patientswith a newdiagnosis ofNMIBC
was selected. Patients with benign prostatic hyperplasia (BPH),muscle invasive bladder carcinoma (MIBC), carcinoma in situ (CIS),
and NMIBC recurrent tumors were not included due to their different clinical behavior. Clinical history was obtained by means of
anamnesis and physical examination, and preoperative imaging and urine cytology were carried out for all patients. Then, patients
underwent conventional transurethral resection (TURBT) and some proteomic analyses quantified the biomarkers (p53, neu, and
EGFR). A postoperative follow-upwas performed to detect relapse and progression. Clusteringswere performed to find groupswith
clinical, molecular markers, histopathological prognostic factors, and statistics about recurrence, progression, and overall survival
of patients with NMIBC. Four groups were found according to tumor sizes, risk of relapse or progression, and biological behavior.
Outlier patients were also detected and categorized according to their clinical characters and biological behavior.
1. Introduction
Bladder cancer (BC) is one of the most frequently occurring
tumors worldwide [1]. Most BCs are transitional cell carcino-
mas (TCC), that is, a cancer that begins in cells that normally
make up the inner lining of the bladder. TCC, also known
as urothelial carcinoma, is the most common type of bladder
cancer. The cancer starts in cells, called transitional cells, in
the bladder lining (urothelium).
Bladder cancer is staged according to the degree of tumor
invasion into the bladder wall. Carcinoma in situ (stage Tis)
and stages Ta and T1 are grouped as nonmuscle invasive blad-
der cancers (NMIBC) because they are restricted to the inner
epithelial lining of the bladder and do not involve the muscle
wall. Of the NMIBC, stage Ta tumors are confined to the
mucosa, whereas stage T1 tumors invade the lamina propria.
T1 tumors are regarded as being more aggressive than Ta
tumors. Muscle invasive bladder cancer (MIBC) may extend
into the muscle (stage T2), the perivesical fat layer beyond
the muscle (stage T3), and adjacent organs (T4). Metastatic
tumors involve lymph nodes (N1–3) or distant organs (M1).
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Approximately 75% of patients with TCC present a dis-
ease at a noninvasive stage that involves only the inner lining
of the bladder [2]. The remaining 25% of newly diagnosed
bladder cancers are MIBC and have a higher risk of cancer-
specific mortality [3] with the need of aggressive radical
surgery or radiotherapy, with or without chemotherapy.
The cellular morphology of TCC is graded according to
the grading of cellular differentiation.The grading consists of
well-differentiated (grade 1), moderately differentiated (grade
2), and poorly differentiated (grade 3) tumors. Grading of
cell morphology in NMIBC is important for establishing
prognosis because grade 3 tumors are themost aggressive and
the most likely to become invasive.
NMIBC is a heterogeneous group of tumors. Between
30% and 90% will relapse within 5 years. One group (70%)
will have a good survival rate but a high risk of recurrence
with the same degree of clinical aggressiveness and a global
survival at 5 years greater than 80% [4]. A minor but
not insignificant proportion of patients (30%) [4, 5] have
a high risk of progression with a severe worsening of the
prognosis and therapeutic options [6].Themain treatment of
NMIBC consists of transurethral resection (TURBT) followed
in the majority of the cases by intravesical instillations of
chemotherapeutic agents or immunotherapy.
Theheterogeneity ofNMIBC in terms of both histological
origin and clinical behavior means that clinical parameters
such as tumor grade and stage are not yet enough to
accurately predict biological behavior or to guide treatment
reliably. Although these parameters provide a certain degree
of tumor biological potential, a significant degree of tumor
heterogeneity remains even within prognostic subgroups.
The need for accurate diagnosis, continuous surveillance,
and possible repeated treatments and the need to anticipate
whichNMIBCwill progress into an invasive diseasemake BC
one of the most expensive tumors in terms of total medical
care expenditures [7] with an estimated cost of US$96,000
to US$187,000 per patient from diagnosis to death in the
United States [7]. Accordingly, the major goals in treating
patients with NMIBC are to prevent the high number of
recurrences and to prevent muscle invasive progression. A
more individually tailored follow-up scheme for NMIBC
patients depending on their risk profile would help to reduce
patient burden and costs. With these aims, new tools to aid
diagnosis, assess prognosis, identify optimal treatment, and
monitor progression of NMIBC are urgently required.
The unprecedented progress on clinical prognostic accu-
racy with the emergence of risk calculators, artificial neural
networks, and cancer genetics are rapidly affecting the clinical
management of solid tumors. Some of them are now an
integral part of routine clinical management for patients with
lung, colon, and breast cancer. In sharp contrast, molecular
biomarkers have been largely excluded from current man-
agement algorithms for urologicmalignancies. Presently, risk
associations are beginning to be included in management
algorithms of NMIBC [8], but risk groups and validated
prognostic molecular biomarkers that can help clinicians to
identify patients in need of early, aggressive management are
lacking.
Hierarchical clustering (HC) applied to structured
databases is used as an aid to represent medical domain
knowledge substructures to simplify the generation process
of the databases through clustering. As a result, it is possible
to identify interesting relationships and patterns among the
data and represent them in the form of rules.
Based on this background there is a belief of the use-
fulness to employ a prior database used in several studies
of our research group [9–13], which includes traditional risk
factors, risk groups, and somemolecular markers, to perform
a cluster analysis to try to discover nonevident patterns in the
dataset.
The paper is organized as follows. Section 2 presents
the research hypotheses and goals of the paper. Section 3
describes the bladder cancer, from epidemiology to etiology,
and prognostic factors. Section 4 presents the population
investigated and the clinical methodology used to obtain
the data. The hierarchical clustering analysis of the data is
presented and discussed in Section 5.The paper is concluded
in Section 6 with some considerations and perspectives for
future research.
2. Research Hypotheses and Goals
The research hypothesis is that a combined molecular and
histopathological analysis of NMIBC might be related with
predicting outcomes and designing treatments of NMIBC.
There are three main goals with this research:
(i) to find the intrinsic grouping in a set of data with
clinical, molecular markers and statistics about recur-
rence, progression, and overall survival of patients
with NMIBC;
(ii) to develop a knowledge discovery in databases
(KDD) approach for discovering possible relation-
ships between the concentration of different molec-
ular markers and clinical and histopathological prog-
nostic factors of NMIBC;
(iii) to investigate if a combined clinical and molecular
classification of NMIBC based on a developmental
biology approach can provide additional prognos-
tic information by using a hierarchical clustering
exploratory data analysis.
3. Bladder Cancer
3.1. Epidemiology of BC. BC is themost commonmalignancy
of the urinary tract, the 7th most common cancer in men
and the 17th in women [14].The worldwide age-standardized
incidence rate is 9 per 100,000 for men and 2 per 100,000 for
women (2008 data) [15].
In the European Union (EU), the age-standardized inci-
dence rate is 27 per 100,000 for men and 6 per 100,000 for
women [1]. The incidence of BC varies between regions and
countries; in Europe, the highest age-standardized incidence
rate has been reported in Spain (41.5 in men and 4.8 in
women) and the lowest in Finland (18.1 in men and 4.3 in
women) [15].
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Worldwide age-standardized mortality rate is 3 for men
versus 1 per 100,000 for women. In the EU, the age-
standardized mortality rate is 8 for men and 3 per 100,000
for women, respectively [1]. In 2008, BC was the eighth most
common cause of cancer-specific mortality in Europe [15].
The incidence of BChas decreased in some areas, possibly
reflecting the decreased impact of causing agents, mainly
smoking and occupational exposure [16]. Mortality from BC
has also decreased, possibly reflecting an increased standard
of care [17].
3.2. Etiology of BC. Tobacco smoking is the most important
risk factor for BC, accounting for approximately 50% of
the cases [3, 18], because tobacco smoke contains aromatic
amines and polycyclic aromatic hydrocarbons, which are
renally excreted. Cigarette smokers have a two- to fourfold
increased risk of bladder cancer compared with nonsmokers
[19], and the risk increases with increasing intensity and
duration of smoking [20]. On cessation of smoking, the risk
of bladder cancer falls>30% after 1–4 years and by >60% after
25 years but never returns to the risk level of nonsmokers [1].
Occupational exposure to aromatic amines, polycyclic
aromatic hydrocarbons, and chlorinated hydrocarbons is the
second most important risk factor for BC, accounting for
about 10% of all cases. This type of occupational exposure
occurs mainly in industrial plants processing paint, dye,
metal, and petroleum products [3, 21, 22].
Although the significance of the amount of fluid intake is
uncertain, the chlorination of drinking water and subsequent
levels of trihalomethanes are potentially carcinogenic, while
exposure to arsenic in drinking water increases the risk
[3]. The association between personal hair dye use and risk
remains uncertain; an increased risk has been suggested in
users of permanent hair dyes with an NAT2 slow acetylation
phenotype [23, 24]. The impact of diet and environmental
pollution is less evident.
Exposure to ionizing radiation is connected with
increased risk. It is suggested that cyclophosphamide and
pioglitazone are weakly associated with BC risk [3]. Schis-
tosomiasis, a chronic endemic cystitis, based on recurrent
infection with a parasitic trematode, is a cause of BC [3].
Finally, there is increased evidence that genetic predispo-
sition may influence the incidence of TCC of the bladder [3],
especially via its impact on susceptibility to other risk factors
[3, 25].
3.3. Prognostic Factors (PF) of NMIBC. As previously seen,
the NMIBC is a heterogeneous group of tumors whose prog-
nosis and therapeutic indications are very difficult to establish
at the diagnosis time. Although TURBT is an essential
diagnostic tool and an effective treatment for bladder cancer,
45% of patients will have tumor recurrence within 12 months
of TURBT alone. Tumor recurrence can be attributed to a
combination of missed tumors, incomplete, initial resection,
reimplantation of tumor cells after resection, and tumor
occurrence in high risk urothelium. Several factors influence
the recurrence rate, for instance, clinical and pathological
results, applied treatments, and diagnostics.
There are two fundamental risks attributed to NMIBC:
the risk of recurrence without worsening the grade or stage
and the risk of progression to MIBC. So, according to this
behavior, basically, NMIBC can be classified into three groups
of patients. A minority of patients (20–30%) have a relatively
benign type of TCCwith a low recurrence rate.These low risk
tumors do not showprogression.The largest group of patients
includes those who frequently develop a NMIBC recurrence
but seldom experience progression. A third, small group of
patients, includes those who have a relatively aggressive non-
muscle invasive tumor at presentation. Despite maximum
treatment, up to 45% of these patients will develop MIBC.
The desire to predict which NMIBC will become MIBC and
will develop disseminated disease has stimulated the study
of factors with possible prognostic value; these are called
prognostic factors (PF).
3.3.1. Clinical PF. The current clinicopathology-based prog-
nostic approaches for predicting recurrence and progression
in NMIBC divides the factors into three groups: PF based on
clinical; endoscopic; and pathological findings [26–33].
Prognostic factors are based on clinical findings:
(i) primary or recurrence,
(ii) prior recurrence rate,
(iii) use of intravesical therapy.
PF are based on endoscopic findings:
(i) number of tumors,
(ii) tumor size.
PF are based on pathologic findings:
(i) tumor grade,
(ii) tumor stage,
(iii) association with carcinoma in situ (CIS).
In our database we selected only primary tumors with no
concomitant CIS. Previously recurrent tumors were excluded
because of their molecular markers and their natural history
could be altered due to the previous use of intravesical
chemo- or immunotherapy, usually employed in this kind
of tumors. In the same way, concomitant CIS patients were
excluded because CIS has a clearly different molecular devel-
opmental pathway [34, 35] and a clearly worse prognosis.
Several authors have tried to classify NMIBC risk groups
by trying to predict the possible evolution, in order to design
strategies for treatment and monitoring.
Parmar et al. [26] established 3 different groups of risk of
recurrence: Group 1 (single tumor and negative cystoscopy at
3rd month); Group 2 (multiple tumor, or positive cystoscopy
at 3rd month); and Group 3 (multiple tumor and positive
cystoscopy at 3rd month). The percentage of patients free of
recurrence at 2 years was 74% in Group 1, 44% in Group
2, and 21% in Group 3. In this classification, interesting for
its simplicity, the introduction of positive cystoscopy at 3rd
month as a risk factor provides a high degree of differentiation
of tumor recurrence; however, it is not suitable to assess the
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progression or tumor mortality, which was not accounted for
by this author.
Fradet [36] studying 382 patients with initial NMIBC
showed that the main PF for recurrence in their series were
tumor multiplicity, size, stage, and tumor grade, defining
what they called adverse tumor characteristics (ATC). With
this classification, recurrence and progression at 1 year were,
respectively, 21 and 0% in the low risk group, 36 and 1% in the
intermediate risk group, and 66 and 9% in the high risk group.
CCAFU [37] also classified the NMIBC into three categories
according to progression risk (low risk groups, intermediate,
and high).
When using these risk groups, however, no distinction
is usually drawn between the risk of disease recurrence
and disease progression. Although prognostic factors may
indicate a high risk of recurrence, the risk of progression
might still be low, while other tumors might have a high risk
of both recurrence and progression.
In order to predict separately the short- and long-term
risks of disease recurrence and progression in individual
patients, the group of Millán-Rodŕıguez et al. [38] has also
designed its own risk classification based on the PF NMIBC
discussed above, with the novelty of having each group
assigned a specific weight PF recurrence, progression and
mortality, stratifying the different variables depending on
the degree and the association of Kish. Accordingly, and
analyzing 1,529 patients with NMIBC, they established three
groups with different risks of recurrence, progression and
mortality. Risk groups were classified as low (grade 1 stage
Ta disease and a single grade 1 stage T1 tumor), intermediate
(multiple grade 1 stage T1 tumors, grade 2 stage Ta disease,
or a single grade 2 stage T1 tumor), and high (multiple grade
2 stage T1 tumors, grade 3 stages Ta or T1 disease, and any
stage disease associatedwithCIS), with significant differences
on recurrence, progression, and overall survival among the 3
groups. Low and intermediate risk patients showed 37% and
45% risk of recurrence, respectively, without significant risk
for progression or death from bladder cancer. By contrast, in
the high risk category the incidence of recurrence, progres-
sion, and mortality was 54%, 15%, and 9.5%, respectively.
More recently, the European Organization for Research
and Treatment of Cancer (EORTC), Genito-Urinary Cancer
Group (GUCG), developed a scoring system and risk tables
[8] based on the six most significant clinical and pathological
factors:
(i) number of tumors;
(ii) tumor size;
(iii) prior recurrence rate;
(iv) T category;
(v) presence of concurrent CIS;
(vi) tumor grade.
The basis for the EORTC risk tables was a combined anal-
ysis of individual patient data from 2596 NMIBC patients
included in seven randomized EORTC trials [8]. A sim-
ple scoring system was derived based on six clinical and
pathological factors (number of tumors, tumor size, prior
recurrence rate, T stage, presence of concomitant CIS, and
tumor grade). Based on available prognostic factors and in
particular data from the EORTC risk tables, the EAU Guide-
lines Panel recommends stratification of patients into three
risk groups that will facilitate treatment recommendations.
The prognostic value of the EORTC scoring system has
been confirmed by data from the Clube Urológico Español
de Tratamiento Oncológico (CUETO) patients treated with
BCG and by long-term follow-up in an independent patient
population (125,126). The CUETO risk calculator is available
at http://www.aeu.es/Cueto.html [39, 40].
For our database, we used a modification of the risk
groups classifications proposed by Parmar et al. [26] and
Millán-Rodŕıguez et al. [38], grouping low and intermediate
risk groups into the same risk group, trying to avoid the data
dispersion, because of the small number of patients in each
group and the small prognostic differences between low and
intermediate risk groups.
3.3.2. Molecular PF. With increasing understanding of the
cellular mechanisms underlying the development of molecu-
lar pathways involved in urothelial oncogenesis, somemolec-
ular prognostic factors are being proposed to identify patients
in need of surveillance and aggressive treatment.
Originally defined to represent the analysis of the entire
protein component of a cell or tissue, proteomics now encom-
passes the study of expressed proteins, including identifica-
tion and elucidation of the structure-function relationship
under healthy conditions and disease conditions, such as
in cancer. In combination with genomics, proteomics can
provide a holistic understanding of the biology underlying
disease processes.
Cancer proteomics encompasses the identification and
quantitative analysis of differentially expressed proteins rel-
ative to healthy tissue counterparts at different stages of
disease, from preneoplasia to neoplasia. Expression analysis
directly at the protein level is necessary to unravel the critical
changes that occur as part of disease pathogenesis. This is
because proteins are often expressed at concentrations and
forms that cannot be predicted from mRNA analysis [41].
Many molecular markers have been studied in NMIBC
[42], including deletion or expression of mutated forms of
the tumor-suppressor genes, p53 and retinoblastoma, and
expression of the different products of the tyrosine kinase
receptor (TKR) family.
The epidermal growth factor receptor (EGFR) is a mem-
ber of the TKR family, a group of receptors which are all
encoded by the c-erbB oncogenes. There are four known c-
erbB oncogenes whose transcription produces a variety of
protein products that play a physiological role in coordinated
cell growth and tissue repair. Pathological expression of these
proto-oncogenes is associated with the loss of coordination
of cell growth that typifies malignancy.
A series of studies have indicated the potential prognostic
value of evaluating expression levels of TKR genes such as
FGFR3, EGFR, ERBB2 (HER/neu), and ERBB3 in patients
with NMIBC and muscle invasive bladder cancer (MIBC)
[34, 43, 44].
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Overexpression of EGFR in bladder cancer has been
widely reported [45–48] and several studies have shown
EGFR positivity to be associated with high tumor stage,
tumor progression, and poor clinical outcome [46, 48, 49].
The mechanism by which EGFR expression is associated
with poor prognosis is not entirely clear, although there
is some evidence linking EGFR stimulated activation of
activator protein-1 transcription factor with induction of
matrix metalloproteinase activity [50].
TheHER2/neu gene encodes a glycoprotein with intrinsic
tyrosine kinase activity, another member of the family TKR.
The HER2/neu encoded protein molecule occupies a critical
position in the biochemical pathways responsible for the
transduction of mitogenic signals from a variety of growth
factor receptors. In addition to its role in regulating normal
cellular proliferation, overexpression of the HER2/neu gene
appears to play a role in neoplastic cell growth [51].
The incidence of overexpression of HER2/neu in bladder
cancer is one of the highest among all human malignancies,
ranging from 9% to 34% of the cancers tested [52–55].
In transitional bladder cell carcinoma, it was found that
HER2 is overexpressed with a greater frequency in higher
grades (40%) and stages (38%) than lower grades (0%) and
stages (8%) [56]. Several studies have suggested a negative
prognostic role for HER/neu amplification or overexpression
in MIBC [57–60]. Using multivariate analysis, Bolenz et al.
[55] found that patients harboring tumors with HER/neu
overexpression were twice as likely to experience recurrence
and to die from their cancer, compared to patients with
HER/neu-negative tumors.
A subset of high grade NMIBCs contains HER2 ampli-
fication and is associated with markedly aggressive behav-
ior [61]. The results obtained by quantitative methods in
other studies showed HER2/neu oncoprotein to be more
significantly expressed in the malignant group compared to
the benign and normal groups [54], and they concluded
that the quantitative assessment of HER2/neu expression in
malignant tumors aided by other proliferation markers such
as synthetic phase fraction (SPF),DNA index (DI), and ploidy
is useful in selecting patients formore aggressive treatment or
for predicting outcome.
TP53 tumor suppressor gene is considered to play a
significant role in carcinogenesis. Mutations in the TP53
are the most frequent genetic abnormalities encountered in
human malignancies, including urinary bladder carcinoma
[62]. It has already been established that the half-life of a
mutated p53 protein is considerably longer than that of the
wild-type p53 protein [63]. The accumulation of the mutated
p53 protein in the nuclei of the malignant cell is the main
reason for increased detection level by immunohistological
methods, including immunofluorescence.
Many previous studies have established that both p53
gene mutations and immunohistochemically detected p53
expression are independent prognostic biomarkers in CCT,
indicating that p53 stabilization not encoded by mutant
gene could also produce aberrant downstream signaling
pathways, with a central role in apoptotic regulation [64,
65]. Progression of NMIBC to higher-grade muscle invasive
disease is also due to alterations in TP53 and RB1. Early
studies by Sarkis et al. [66, 67] found TP53 alterations to
be strong independent predictors of disease progression in
patients with NMIBC, MIBC, and CIS. Recent studies have
supported these findings by showing an independent role
of TP53 alteration in predicting disease-free survival and
disease-specific survival in patients with pT1 and pT2 tumors
who have undergone cystectomy [68].
Digital quantitative detection of nuclear p53 by immuno-
fluorescence staining of histological samples seems to provide
more objective and reproducible values corresponding to
p53 protein concentration in cell’s nuclei than the traditional
scoring system of counting the positively stained cells [69].
As it has been proved in previous publications of our
working group [9–13] quantitative expression analysis of
these proteins seems to be helpful to establish prognosis in
BC.
4. Population Investigated
4.1. Clinical Methodology. This analysis used a subpopulation
of a previous clinical database with three different groups of
patients, NMIBC, MIBC, and Benign Prostatic Hyperplasia
(BPH) patients. 45 patients with a new diagnosis of NMIBC
were selected. Patients with BPH, MIBC, CIS, and previous
NMIBC recurrent tumors were not included in this database
because of their different clinical behavior.
Anamnesis andphysical examinationwith clinical history
were previously carried out in order to collect clinical factors
(age, sex, smoking status, and alcohol consumption and
presentation mode).
As part of a preoperative staging, preoperative imaging
(renal and bladder ultrasound, intravenous urography, com-
puted tomography, or cystoscopy) and urine cytology were
carried out before the diagnosis of all patients.
After that, patients underwent conventional TURBT and
the following data were collected: multiplicity, size, and
aspect. TURBT was completed with a standardized multiple
biopsy of the bladder surface in order to exclude the presence
of concomitant CIS.
Once the TURBT was finished, the tumor tissue obtained
was divided into two specimens: one of them for the
histopathological study and the other one for protein expres-
sion studies.
Histopathological diagnosis was performed by a single
pathologist. Grading was established using the OMS classifi-
cation [70]. Staging was performed by the UICC criteria 1997
staging system [71]. Patients with biopsies that showed the
presence of concomitant CIS were excluded from the study.
The samples extracted in the surgery room were sent to
the proteomic laboratory for a quantification of the following
biomarkers:
(i) p53 protein: quantified in the cytosol by a technique
of immunoluminescence (LIA);
(ii) neu protein: determined using a quantitative enzyme
linked immunoassay (ELISA);
(iii) EGFR: quantified in membranes by radioimmunoas-
say (RIA).
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Then, a stratified protocol of postoperative adjuvant intrav-
esical therapy and standard follow-up for patients diagnosed
NMIBC with cytology and cystoscopy or ultrasound was
performed for preventing and detecting tumor recurrence
and/or progression.
4.2. Dataset. The dataset used in the experiments is com-
posed of 45 patients undergoing TURBT for NMIBCwithout
the presence of concomitant CIS. Table 1 summarizes the 67
variables measured for each patient, their description, and
range.
5. Hierarchical Clustering Analysis
The numerical analyses performed here with the dataset
emphasized the use of clustering algorithms for finding
hierarchical groups of objects in an unsupervised way [72–
74].The first steps involved preparing the dataset for analysis,
which included cleansing and normalizing the data. Then,
three different clustering analyses were performed: using only
those variables with no missing values; using all variables,
but replacing missing values; and using only those variables
selected by experts. The different analyses allowed us to
detect, remove, and explain anomalies in the dataset and
to cluster patients based on neu ranges and risk groups,
with a different prognostic of progression or recurrence.
The method and experiments are detailed in the following
sections.
5.1. Single-Linkage Hierarchical Clustering. Clustering, in
data mining, tries to identify the distribution of patterns
and intrinsic correlations in datasets by partitioning the data
points into similarity groups. Clustering enhances the value
of existing databases by revealing rules in the data. These
rules are useful for understanding trends,making predictions
of future events from historical data, or synthesizing data
records into meaningful clusters [72–74].
Clustering algorithms usually employ a distance metric
(e.g., Euclidean) or a similarity measure to partition the
database, such that data points in the same partition are
more similar than points in different partitions. Hierarchical
clustering is one of the most frequently used methods in
unsupervised learning. Given a set of data points, the output
is an upside down tree, known as a dendrogram, whose leaves
are the data points andwhose internal nodes represent nested
clusters of various sizes. The tree organizes these clusters
hierarchically, where the hope is that this hierarchy agrees
with the intuitive organization of real-world data.
The method used in the clustering experiments per-
formed in this paper is named single-linkage. This is an
agglomerative hierarchical method in which new clusters are
created by combining the most similar groups. The initial
clustering is formed by a singleton, that is, a single object, and
at each iteration a new cluster is formed by joining two of the
most similar groups of the previous iterations. In the single-
linkage, the distance between the new group and the others
is determined as the shortest distance among the elements of
the new and the remaining groups.
5.2. Data Cleansing. Data preprocessing, or data preparation,
manipulates and transforms data so that the knowledge
contained in it can be more easily and accurately extracted
[75, 76].The best way to preprocess the data depends on three
main issues: the database problems (e.g., inconsistency and
noise); what use is intended from the data; and how the data
analysis tools to be used work.
The first preprocessing step performed with the dataset
was to remove constant-valued variables, identifiers (IDs),
variables with a high number of missing values, and dates.
Table 2 presents the variables that were removed from the
original dataset and why.
5.3. Analysis with No Missing Values. In this first analysis,
only those variables without missing values were considered,
totaling 58 out of 67 variables, as follows: Age; Gender;
Tabaco; Alcohol; Af; Mfumador; Hematuri; Irritat; Dolor-
sup; Otross; Diagn; Tumor; Hem; Hb; Hcto; Citesp; Citar;
Eco; Uiv; Ct; Cistosc; Multiple; Tam; TAM3CM; Aspect;
ASPESUPE; Tto; ADYUV; Oncot; Mytom; Bcg; Bmn; Jewett;
G; G23; Tnm; GRIES; GRX; Ap; Tipoap; p53iha; p53ria;
Neu; Recidiv; Progres; Nrecidiv; Numrecp; Metas; Muerte;
Mporca; Recm; Logneu; Superv; Tprogre; Tmetas; Np53ria;
Nneu; Edad70.
Figure 1(a) shows the dendrogram of the hierarchical
clustering performed on all patients and only those variables
with no missing values. It can be observed that patients 10,
13, and 28 have profiles substantially distinct from the others,
thus being treated as anomalies. To better investigate the data
and search for groups of patients’ profiles, the anomalous
patients (10, 13, and 28) were removed from the dataset and
a new hierarchical clustering was performed, as depicted in
Figure 1(b).
By looking at Figure 1(b) the presence of five clusters of
patients can be observed (represented here by their IDs):
(i) Cluster 1: 6, 30, 35;
(ii) Cluster 2: 1, 3, 4, 7, 11, 14, 15, 17, 19, 20, 22, 24, 26, 29, 31,
34, 37, 38, 39, 42, 45;
(iii) Cluster 3: 2, 5, 12, 16, 18, 27, 44;
(iv) Cluster 4: 8, 21, 23, 33, 36, 40, 41, 43;
(v) Cluster 5: 9, 25, 32.
After an analysis of the original dataset and comparison with
the groups found by the algorithm, it is possible to note a
subdivision of patients based on ranges of the neu variable,
as follows:
(i) Cluster 1: neu ≈ 400HNU/mL;
(ii) Cluster 2: 600 ≤ neu ≤ 1,100HNU/mL;
(iii) Cluster 3: neu < 400HNU/mL;
(iv) Cluster 4: 1,500 ≤ neu ≤ 1,900HNU/mL;
(v) Cluster 5: 1,200 ≤ neu ≤ 1,400HNU/mL.
The anomalous profiles found presented a very large neu: neu
> 1,900HNU/mL. No association between these neu clusters
and classical risk factors or risk groups was found.
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Table 1: Variables measured and available in the dataset.
Name Description Values Significance
Type Type of sample 1/2/3 NMIBC/MIBC/control
Age Diagnosis age Numeric Years
N History Identification number Numeric —
Gender Gender 1/2 Male/female
Fdiagn Diagnostic data Date DD/MM/YYYY
Tobacco Tobacco smoking 0/1 No/yes
Alcohol Alcohol consumption 0/1 No/yes
Af Family history of BC 0/1 No/yes
Mfum More than 20 cigarettes a day 0/1 No/yes
Otrosf Other risk factors of BC Text Not analyzable
Hematuri Haematuria 0/1 No/yes
Irritat Irritative syndrome 0/1 No/yes
Dolorsup Suprapubic pain 0/1 No/yes
Otros Other symptoms 0/1 No/yes
Diagn Diagnostic type 1/2 Symptomatic/incidental
Tumor Number of tumors Numeric Numeric
Creat Creatinine Numeric mg/dL
Got GOT Numeric U/L
Gpt GPT Numeric U/L
Hem Number of red blood cells Numeric E6/uL
Hb Haemoglobin Numeric g/dL
Hcto Hematocrit Numeric %
Ca Calcium Numeric mg/dL
P Phosphorum Numeric mg/dL
Falc Alcaline phosphatase Numeric U/L
Citesp, Citarr; eco, UIV; CT, cistosc Diagnosis test performed Text Not analyzable
Multiple Multiplicity 1/2 Single/multiple
Tam Size (cm) numeric cm
TAM3CM Size ≥3 cm 1/2 No/yes
Aspect Endoscopic aspect 1/2/3 1 Superficial/2 infiltrative/3 intermediate
ASPESUP Superficial aspect 1/2 Yes/no
Tto Type of adjuvant therapy Text Not analyzable
ADYUV Adjuvant therapy 1/2 Yes/no
Jewett Histologic staging 1/2/3 A/B/C-D
G Grade 1/2/3 G1/G2/G3
G23 Grades 2 or 3 1/2 No/yes
Tnm TNM 1/2 Ta/T1
Gries EORTC risk group 1/2 Low-intermediate/high
Grx Millan risk group 1/2 Low-intermediate/high
AP, tipoAP Type of BC 1/2/9 Not analyzable TCC/SC/other
p53iha P53 immunohistochemistry 1/2/3 +/++/+++
p53ria P53 quantified Numeric ng/ml
Neu Prot p185 quantified Numeric HNU (0.05 fmol/mg)/ml
p16 Prot p16 immunohistochemistry 1/2/3 +/++/+++
Recid Relapse 1/2 Yes/no
Fechare First relapse data Date DD/MM/YYYY
narecid Number of relapses Numeric Number
narecidp Number of relapses till progression Numeric Number
Prog Progression 1/2 Yes/no
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Table 1: Continued.
Name Description Values Significance
Fprog Progression date Date DD/MM/YYYY
Metas Metastatic disease 1/2 Yes/no
Muerte Death 1/2 Yes/no
Fechmuerte Date of death Date DD/MM/YYYY
Mporca Cancer specific mortality 1/2 Yes/no
Recm Number of relapses till death Numeric Number
fechaultre Last Revision Date Date DD/MM/YYYY
Egfr EGFR quantified Numeric EGFR fmol/protein mg
Logneu Neu logarithm Numeric Number of months
Super Survival (months) Numeric Number of months
Ile Relapse-free survival Months Number of months
Tprogre Progression-free survival Months Number of months
Tmetas Metastatic disease-free survival Months Number of months
Np53ria p53 RIATertile 1/2/3 Tertile 1/tertile 2/tertile 3
Nneu NeuTertile 1/2/3 Tertile 1/tertile 2/tertile 3
Negfr EGFRTertile 1/2/3 Tertile 1/tertile 2/tertile 3
Filtro NMIBC
edad70 Older than 70 years 1/2 Yes/no





















Figure 1: Hierarchical clustering of the NMIBC patients removing variables with missing values. (a) Clustering of the whole dataset. (b)
Clustering of the dataset after removing the anomalous patients 10, 13, and 28.
5.4. Analysis Replacing Missing Values. In the second set of
experiments performed, all 67 variables were used, but those
with missing values were replaced by the average in case
of numeric variables, or by the mode in case of categorical
variables. Table 3 summarizes the replacement values used
for each variable with missing values.
In this case, the hierarchical clustering shown in
Figure 2(a) indicates only two anomalous profiles, patients 13
and 28. After removing them from the dataset, the following
clusters emerge (Figure 2(b)):
(i) Cluster 1: 1, 2, 3, 4, 5, 6, 7, 11, 12, 14, 15, 16, 17, 18, 19, 20,
22, 24, 26, 27, 29, 30, 31, 34, 35, 37, 38, 39, 42, 44, 45;
(ii) Cluster 2: 8, 21, 23, 33, 36, 40, 41, 43;
(iii) Cluster 3: 9, 10, 25, 32.
In this case, an analysis of the groups formed leads to
the observation of the following neu ranges: Cluster 1
(1,250HNU/mL ≤ neu ≤ 1,550HNU/mL); Cluster 2 (neu >
1,550HNU/mL); and Cluster 3 (neu < 1,200HNU/mL).
No association between these neu clusters and classical
risk factors or risk groups was found.
5.5. Expert Selection of Relevant Variables. In this last exper-
iment, the goal was to observe if there is any relationship
between the molecular markers (proteins neu, EGFR, and
p53) and the tumoral tissue of NMIBC. To investigate that, a
subset of the variables was selected manually and the cluster-
ing algorithm was applied. The following variables were cho-
sen: Age, Gender, Tabaco, Tumor, Multiple, Tam, TAM3CM,
ASPESUPE, G, G23, Tnm, GRIES, GRX, Tipoap, p53iha,
p53ria, neu, Recidiv, Progres, Nrecidiv, Metas, Muerte, Egfr,
Logneu, Superv, Ile, Tprogre, Tmetas, Np53ria, Nneu, Negfr,
and Edad70. The patients with missing values (3, 8, 10, 11,
17, 18, 22, 23, 24, 27, 28, 31, and 34) were removed from the
BioMed Research International 9






















Figure 2: Hierarchical clustering of the NMIBC patients using all variables. (a) Clustering of the whole dataset. (b) Clustering of the dataset
after removing the anomalous patients 13 and 28.
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dataset. The results are presented in Figure 3. In Figure 3(a)
the clustering of the whole dataset is presented, and the
presence of eight outliers can be observed: 13, 26, 30, 35, 37,
38, 44, and 45.
By looking at Figure 3(b) it is possible to observe four
clusters of patients who can be subdivided into risk groups:
(i) Cluster 1: low riskwith no progression and recurrence;
(ii) Cluster 2: high risk with no recurrence (or late
recurrence) and no progression;
(iii) Cluster 3: low risk with early recurrence and no
progression;
(iv) Cluster 4: high risk with recurrence and progression.
Outlier patients can always be grouped in one of the different
clusters according to their clinical characters (size, number,
grade, stage, etc.) but were excluded by the algorithm because
one or more molecular markers were out of range, as shown
in Tables 4 and 5.
5.6. Discussion. Progress in data storage and acquisition has
resulted in a growing number of enormous databases. The
information contained in these databases can be extremely
interesting and useful; however, the amount is too large
for humans to process manually. Data mining is defined as
part of knowledge discovery in databases and draws on the
fields of statistics, machine learning, pattern recognition, and
database management and can be able to extract interesting
and useful material from these large datasets.
Using a hierarchical algorithm it was possible to find
two different cluster associations based on HER2/neu levels.
None of these associations was significantly correlated with
any of the clinicopathologic data studied (neither classical
risk factors nor risk groups).These data support the previous
assertion of another working group, which suggested that the
quantitative assessment of HER2/neu expression by ELISA in
BC was not significantly associated with stage or grade and
has no prognostic significance by itself but only aided by other
proliferation markers such as SPF, DI, and ploidy [54].
By using a hierarchical clustering algorithm, an interest-
ing distribution of patients into four different groups (clus-
ters) with different biological behaviors and prognosis could
be found. Cluster 1 is composed of unique tumors, low size
(<3 cm), low grade, and low stage, with a low risk of relapse or
progression, and with a biological behavior according to the
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Table 4: Clinical and molecular characteristics of the different clusters.
Attribute Cluster 1 Cluster 2 Cluster 3 Cluster 4
Age∗ 61 years; 18 67 years; 9 70 years; 9 82 years; 9
(23–73) (52–79) (60–82) (72–93)
Multiplicity No: 100% No: 20% No: 40% No: 50%
Yes 0% Yes 80% Yes 60% Yes 50%
TM > 3 cm No: 71% No: 50% No: 60% No: 0%
Yes: 29% Yes: 50% Yes: 40% Yes: 100%
Grade
G1: 83.3% G1: 0% G1: 20% G1: 0%
G2: 16.6% G2: 62.5% G2: 80% G2: 50%
G3: 0% G3: 37.5% G3: 0% G3: 50%
TNM Ta: 100% Ta: 0% Ta: 80% Ta: 0%
T1: 0% T1: 100% T1: 20% T1: 100%
Risk group [26] Low-Int: 100% Low-Int: 0% Low-Int: 80% Low-Int: 0%
High: 0% High: 100% High: 20% High: 100%
Risk group [38] Low-Int: 100% Low-Int: 12.5% Low-Int: 100% Low-Int: 0%
High: 0% High: 87.5% High: 20% High: 100%
p53 (ng/mL)∗ 0.1; 0.2 0.5; 1.2 0; 0 0; 0
(0–0.6) (0–3.40) (0-0) (0-0)
neu (HNU/mL)∗ 748.5; 415.6 775.4; 544.2 1379.9; 184.7 854.4; 497.7
(328–1596.1) (76–1749.1) (1253.0–1698.1) (330.9–1527.2)
EGRF (fmol/mg)∗ 6.9; 4.0 12.5; 12.8 8.5; 4.7 22.8; 17.2
(0.2–11.4) (2.2–16.6) (3.0–15.1) (7.1–39.5)
GS (months)∗ 104; 37 (47–128) 93; 46 (3–135) 84; 47 (23–133) 17; 10 (5–28)
RFS (months)∗ 104; 37 (47–128) 81; 56 (3–135) 9; 4 (4–13) 13; 10 (5–27)
PFS (months)∗ 104; 37 (47–128) 93; 46 (3–135) 84; 47 (23–133) 13; 10 (5–27)
∗Mean; SD (range).





















Figure 3: Hierarchical clustering of the NMIBC patients using the selected variables. (a) Clustering of the whole dataset. (b) Clustering of
the dataset after removing patients 13, 26, 30, 35, 37, 38, 44, and 45.
expected one in patients with these characteristics. Cluster
2 is composed of tumors with a high risk of relapse and
progression (multiplicity, bigger size than 3 cm, high grade,
and high stage) but with no relapse (or a very late superficial
relapse) and no evidence of progression during a long follow-
up period (almost 8 years). Cluster 3 is composed of unique
tumors, with low size, low grade, low stage, and a low risk
of relapse or progression, that shows a very early relapse as
NMIBC and no progression. Cluster 4 is composed of high
risk tumors, with a high risk of progression (multiplicity,
bigger size, high grade, and high stage) and with a biological
behavior according to these characteristics, with an early
relapse, progressing to a MIBC.
Outlier patients can always be grouped into one of
the different clusters according to their clinical characters
(size, number, grade, stage, etc.) and biological behavior
but were excluded by the algorithm because one or more
molecular markers were out of range. Nevertheless, no rules
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Table 5: Clinical and molecular characteristics of the different outliers (patient number).
Attribute Outlier 1 (13) Outlier 2 (26) Outlier 3 (30) Outlier 4 (35) Outlier 5 (37) Outlier 6 (38) Outlier 7 (44) Outlier 8 (45)
Age 77 73 69 72 41 71 80 60
Multiplicity Yes Yes Yes No No No No Yes
TM > 3 cm Yes No No No No No Yes Yes
Grade G3 G2 G2 G2 G2 G2 G3 G2
TNM T1 Ta Ta Ta T1 T1 T1 Ta
Risk group High Low-Int Low-Int Low-Int High High High Low-Int
p53 0 4.7 0.9 0 0 0 0.9 0
Neu 2,125.80 724.5 415.8 459 994 700 385.7 870.6
Egfr 0.5 6.3 15.5 8.6 3.2 1.3 16.4 0
GS (months) 15 35 133 111 131 11 9 106
RFS (months) 15 11 5 11 59 1 3 18
PFS (months) 15 35 133 111 131 1 3 91
Cluster 4 3 3 3 2 4 4 3
Bold: reason for exclusion by the algorithm.
of distribution between clusters and any of the molecular
markers were found.
The small number of patients in the database due to
the restrictive criteria of inclusion (NMIBC, first tumor, no
CIS associated, and disposable molecular markers) and the
retrospective analysis of a preexisted databasewith no specific
design for this use were important limitations of the present
study.
6. Conclusions and Future Work
This paper explored the hypothesis that clinical and histo-
pathological data, together with information from several
molecular markers in patients, helps in the prediction of
outcomes and design of treatments for nonmuscle invasive
bladder cancer. A hierarchical clustering algorithm was
applied to a set of patients to identify clusters of patients
with clinical, molecular markers and prognostic factors and
provide statistics about the recurrence, progression, and
survival of patients.
The results presented showed that the cluster algorithms
can group patients with NMIBC into different molecular
clusters.Thequantitative assessment ofHER2/neu expression
in NMIBC was grouped by the algorithm, but these were
not significantly correlated with clinicopathologic data and
are not useful for predicting the patients’ outcome. Also,
EGFR and p53 showed not to be useful proteins for clustering
patients with NMIBC. However, the hierarchical clustering
algorithm could group patients with NMIBC into different
risk groups with different clinical behaviors and prognosis,
but these ones were not significantly correlated with molecu-
lar markers. Outliers were also detected and explained.
Future investigation includes the use of a larger number
of patients and the inclusion of different molecular markers
in the analyses.
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